{"title":"Immuno-oncology therapies: a looming mid-life crisis?","authors":"Hansoo Kim, D. Liew, Stephen Goodall","doi":"10.18609/ioi.2022.010","DOIUrl":"https://doi.org/10.18609/ioi.2022.010","url":null,"abstract":"","PeriodicalId":73351,"journal":{"name":"Immuno-oncology insights","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41454458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Raiders of the lost art: finding immuno-oncology treasure","authors":"Kishore K Gangangari, A. Murphy, Reni Benjamin","doi":"10.18609/ioi.2022.015","DOIUrl":"https://doi.org/10.18609/ioi.2022.015","url":null,"abstract":"","PeriodicalId":73351,"journal":{"name":"Immuno-oncology insights","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49184802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
W. Lesterhuis, H. Mikkelsen, Jonathan Tobin, Michael Bettess
{"title":"Early-stage investment in immuno oncology: riding the waves of hope & hype","authors":"W. Lesterhuis, H. Mikkelsen, Jonathan Tobin, Michael Bettess","doi":"10.18609/ioi.2022.009","DOIUrl":"https://doi.org/10.18609/ioi.2022.009","url":null,"abstract":"","PeriodicalId":73351,"journal":{"name":"Immuno-oncology insights","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49178942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anand Rotte, C. Heery, B. Gliner, D. Tice, D. Hilbert
{"title":"BCMA targeting CAR T cells using a novel D-domain binder for multiple myeloma: clinical development update","authors":"Anand Rotte, C. Heery, B. Gliner, D. Tice, D. Hilbert","doi":"10.18609/ioi.2022.003","DOIUrl":"https://doi.org/10.18609/ioi.2022.003","url":null,"abstract":"","PeriodicalId":73351,"journal":{"name":"Immuno-oncology insights","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43662382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A need to update paradigms for myeloid cells within the tumor microenvironment to advance immunotherapy","authors":"M. Kinder","doi":"10.18609/ioi.2022.004","DOIUrl":"https://doi.org/10.18609/ioi.2022.004","url":null,"abstract":"","PeriodicalId":73351,"journal":{"name":"Immuno-oncology insights","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42072323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Realizing the potential of NK cell therapy","authors":"Alvin M Shih","doi":"10.18609/ioi.2022.001","DOIUrl":"https://doi.org/10.18609/ioi.2022.001","url":null,"abstract":"","PeriodicalId":73351,"journal":{"name":"Immuno-oncology insights","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48834756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Prognostic Value of Classical Immunoparesis in Multiple Myeloma","authors":"","doi":"10.55085/oi.2022.602","DOIUrl":"https://doi.org/10.55085/oi.2022.602","url":null,"abstract":"","PeriodicalId":73351,"journal":{"name":"Immuno-oncology insights","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77569356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-09-26DOI: 10.18609/ioi.2022.41
Yufei Wang, Sarah E Shelton, Gabriella Kastrunes, David A Barbie, Gordon J Freeman, Wayne A Marasco
Immunotherapy has demonstrated great success in clinical treatment, especially for cancer care. Here we review preclinical models, including cell lines, three dimensional (3D) cultures, and mouse models to support the need for tools enabling the development of novel immune-oncology (I-O) therapies. While in vitro studies have the advantage of being relatively simpler, faster, and higher throughput than in vivo models, they must be designed carefully to recapitulate the biological conditions that influence drug efficacy. The growing prevalence of 3D in vitro and ex vivo models has enabled screening and mechanistic studies in more complex, tissue-like environments containing multiple interacting cell types. On the other hand, syngeneic mouse models have been instrumental in the historical development of immunotherapies and remain an important tool in drug development, despite lacking fidelity to certain aspects of human physiology and pathology. Xenograft and humanized mouse models address some of these challenges, yet present limitations of their own. Successful development and translation of new I-O therapies will likely require thoughtful combination of several of these preclinical models, and we aim to help research and development scientists utilize the appropriate tools and technologies to facilitate rapid transition from preclinical evaluation to clinical trials.
{"title":"Preclinical models for development of immune-oncology therapies.","authors":"Yufei Wang, Sarah E Shelton, Gabriella Kastrunes, David A Barbie, Gordon J Freeman, Wayne A Marasco","doi":"10.18609/ioi.2022.41","DOIUrl":"10.18609/ioi.2022.41","url":null,"abstract":"<p><p>Immunotherapy has demonstrated great success in clinical treatment, especially for cancer care. Here we review preclinical models, including cell lines, three dimensional (3D) cultures, and mouse models to support the need for tools enabling the development of novel immune-oncology (I-O) therapies. While <i>in vitro</i> studies have the advantage of being relatively simpler, faster, and higher throughput than <i>in vivo</i> models, they must be designed carefully to recapitulate the biological conditions that influence drug efficacy. The growing prevalence of 3D <i>in vitro</i> and <i>ex vivo</i> models has enabled screening and mechanistic studies in more complex, tissue-like environments containing multiple interacting cell types. On the other hand, syngeneic mouse models have been instrumental in the historical development of immunotherapies and remain an important tool in drug development, despite lacking fidelity to certain aspects of human physiology and pathology. Xenograft and humanized mouse models address some of these challenges, yet present limitations of their own. Successful development and translation of new I-O therapies will likely require thoughtful combination of several of these preclinical models, and we aim to help research and development scientists utilize the appropriate tools and technologies to facilitate rapid transition from preclinical evaluation to clinical trials.</p>","PeriodicalId":73351,"journal":{"name":"Immuno-oncology insights","volume":"3 8","pages":"379-398"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150782/pdf/nihms-1894239.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9415792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号